Filed in archive
Corporate and Industrial News
by ruth on December 22, 2005
Yesterday, Acologix Inc., a privately held biopharmaceutical company, announced that it has raised $25.3 million in Series C financing, bringing its total raised fund to over $72 million.
Most of the funds will be used to put the company's drug candidate for uremic pruritus in dialysis patients into Phase III clinical trials. Pruritus refers to an unpleasant cutaneous sensation prompting about patients to scratch, and affects approximately 70% of dialysis patients.
In addition this drug candidate, Acologix will continue the development of the following lead compounds: AC-100, a hard tissue regeneration compound, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with Chronic kidney disease.
Source: Acologix
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/12764
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Acologix Secures $24.3M in Series C Financing Round:
|
Rating: 9.50 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
